Extending Drug Exposure Without Systemic Toxicity in NMIBC Treatment

Traditional intravesical chemotherapy for non–muscle-invasive bladder cancer (NMIBC) relies on periodic bolus instillations of gemcitabine. While standard 1- to 2-hour dwell times coat the urothelium, this approach creates a peak-and-trough delivery model, limiting total therapeutic exposure and depth of tissue penetration.

Novel intravesical drug delivery systems aim to eliminate these pharmacokinetic limitations. According to Goutham Vemana, MD, in an interview with CancerNetwork®, an indwelling intravesical system (Inlexzo; formerly TAR-200) transforms local drug kinetics by releasing a steady, continuous dose of gemcitabine over several weeks. This extended contact time significantly enhances drug penetration into deeper bladder tissue layers compared to traditional instillations.

Crucially, studies demonstrate that despite deeper local delivery, the drug is not absorbed into the bloodstream. By providing prolonged, maximal local therapy without triggering systemic toxicity, the system offers a superior pharmacokinetic profile designed to maximize clinical efficacy for bladder cancer.

Vemana is chair of the Department of Urology at Allegheny Health Network (AHN) in Pittsburgh, PA.

Transcript:

Starting from what standard gemcitabine instillations look like historically: these are intravesical treatments where a catheter is placed, and we instill about 2g of gemcitabine into the bladder. It typically dwells in the bladder for 1 to 2 hours, based on patient tolerability, longer is better, and the goal is to coat the surface of the bladder in this chemotherapy to treat and prevent bladder cancer recurrences.

You tend to get a peak-and-trough pattern: a high dose of the drug administered into the bladder, but it is only exposed for a short period of time. The advantage of the gemcitabine intravesical system, TAR-200, is that it is constantly emitting gemcitabine at a steady state for a couple of weeks, so the bladder is exposed to the treatment over a much longer period. Studies have shown that this yields better depth of penetration of the drug into the layers of the bladder. One important finding from these studies is that despite this depth of treatment, the drug does not absorb systemically; it is not being absorbed into the bloodstream. You get this maximal advantage of therapy over a long period of time without systemic exposure, and that is why the efficacy is better.